Product Information
TRIAMTERENE-HYDROCHLOROTHIAZIDE 37.5-25 MG CP is a generic product labeled by Chartwell RX LLC, priced at $0.1181 per EA under NDC 62135052990. Its NADAC has been published 165 times since Aug 9, 2023.
FDA first approved this application on Dec 9, 2011. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
25; 37.5 mg/1; mg/1
Manufacturer
Chartwell RX LLCNDC
62135052990
Classification
Generic
Dosage Form
CAPSULE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
HYDROCHLOROTHIAZIDE; TRIAMTERENEApproval Type
Generic (ANDA)
FDA Application
ANDA201407FDA Approved
12/9/2011
TE Code
AB
On Market Since
12/9/2011
Pharmacological Classes
Price Statistics
The NADAC for TRIAMTERENE-HYDROCHLOROTHIAZIDE 37.5-25 MG CP has been published 165 times since Aug 9, 2023, and over the history we have for it it has declined 17.8%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.1181 per EA |
|---|---|
| All-time high | $0.1436 (Aug 16, 2023) |
| All-time low | $0.0844 (Jul 17, 2024) |
| 52-week high | $0.1221 |
| 52-week low | $0.1128 |
| Median price | $0.1189 |
| Average price | $0.1157 |
| Largest weekly change | +46.0% (Aug 21, 2024) |
| Weeks tracked | 165 |
| Tracking since | Aug 9, 2023 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the TRIAMTERENE AND HYDROCHLOROTHIAZIDE market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Chartwell RX LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
TRIAMTERENE AND HYDROCHLOROTHIAZIDE market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Potassium-sparing Diuretic class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of TRIAMTERENE-HYDROCHLOROTHIAZIDE 37.5-25 MG CP?
The current National Average Drug Acquisition Cost (NADAC) for TRIAMTERENE-HYDROCHLOROTHIAZIDE 37.5-25 MG CP, manufactured by Chartwell RX LLC, is $0.1181 per EA (NDC 62135052990), effective Sep 30, 2026.
How has the price of TRIAMTERENE-HYDROCHLOROTHIAZIDE 37.5-25 MG CP changed over time?
Over the history we have for it, the NADAC for TRIAMTERENE-HYDROCHLOROTHIAZIDE 37.5-25 MG CP has declined 17.8%. It has been tracked across 165 weekly CMS publications since Aug 9, 2023.
What are the highest and lowest recorded NADAC prices for TRIAMTERENE-HYDROCHLOROTHIAZIDE 37.5-25 MG CP?
Since Aug 9, 2023, the NADAC for TRIAMTERENE-HYDROCHLOROTHIAZIDE 37.5-25 MG CP has ranged from a low of $0.0844 (Jul 17, 2024) to a high of $0.1436 (Aug 16, 2023), with a median of $0.1189 per EA.
Are there cheaper alternatives to TRIAMTERENE-HYDROCHLOROTHIAZIDE 37.5-25 MG CP?
No other NADAC-published product currently shares the active ingredient and strength of TRIAMTERENE-HYDROCHLOROTHIAZIDE 37.5-25 MG CP in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures TRIAMTERENE-HYDROCHLOROTHIAZIDE 37.5-25 MG CP?
TRIAMTERENE-HYDROCHLOROTHIAZIDE 37.5-25 MG CP (NDC 62135052990) is labeled by Chartwell RX LLC, and CMS classifies it as a generic product.